Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Operating Income (2016 - 2025)

Cytosorbents' Operating Income history spans 15 years, with the latest figure at $8.6 million for Q4 2025.

  • Quarterly results put Operating Income at $8.6 million for Q4 2025, up 352.08% from a year ago — trailing twelve months through Dec 2025 was -$1.8 million (up 89.02% YoY), and the annual figure for FY2025 was -$1.8 million, up 89.02%.
  • Operating Income for Q4 2025 was $8.6 million at Cytosorbents, up from -$2.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $8.6 million in Q4 2025 to a low of -$9.6 million in Q4 2021.
  • The 5-year median for Operating Income is -$5.2 million (2021), against an average of -$5.2 million.
  • The sharpest move saw Operating Income plummeted 262.98% in 2021, then soared 352.08% in 2025.
  • Year by year, Operating Income stood at -$9.6 million in 2021, then surged by 33.52% to -$6.4 million in 2022, then tumbled by 48.01% to -$9.4 million in 2023, then surged by 63.91% to -$3.4 million in 2024, then soared by 352.08% to $8.6 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at $8.6 million, -$2.9 million, and -$3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.